Publication | Closed Access
Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors
226
Citations
41
References
2003
Year
Endostatin given daily as a 1-hour intravenous infusion was well tolerated without dose-limiting toxicity at doses up to 300 mg/m2.
| Year | Citations | |
|---|---|---|
Page 1
Page 1